March 3, 2022 7:33am
The gene editors have weathered many a storm making their way to clinical trial initiations; will patent ruling canceling certain patent applications, new licensing fees slow their discovery cycle while effecting their share pricing which involves huge sums of money, partners and scientific prestige
Who are or will be the winners?
Pre-open indications: 3 SELLs indications, 2 BUYs Indication and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Only the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.07% (-24 points), S&P futures are DOWN -0.11% (-5 points) and NASDAQ futures are DOWN -0.26% (-38 points)
U.S. stock index futures were tugging on downside moves in pre-open trading Thursday,
European stocks were choppy as tensions remained high over the Ukraine crisis,
Asia-Pacific stocks were largely higher after U.S. stocks bounced back on Wednesday.
Henry’omics:
Markets continued to watch the situation in Ukraine, where fighting entered its second week. Ukrainians maintained the capital city of Kyiv, while heavy shelling hit Maripol and Kharkiv.
Economic Data Docket: jobless claims, which were expected to total 225,000 last week. Productivity, weekly export sales and ISM’s latest report on the services industry outlook also are on tap.
RegMed Investors’ (RMi) closing bell: “a wild up and down open as cell and gene therapy sector closes positive. Share pricing remains very fluid, which means that back and forth is likely to continue.” … https://www.regmedinvestors.com/articles/12324
Ebb and flow –
· March – 1 negative and 1 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... 19 total
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306
UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies https://www.regmedinvestors.com/articles/12320 - added commentary
Companies in my headlights – It’s your decision; I provide ideas and context:
The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NTLA) dazzled the medical community with clinical trial results for its lead candidate, the fight for intellectual property rights related to all its candidates took a sharp turn for the worse.
Could these gene editors be further away from commercializing their first drug than investors expect?
Share pricing is definitely put into flux …
SELL:
Beam Therapeutics (BEAM +$0.70 after Tuesday’s -$4.85 and Monday’s -$3.60) with a pre-open indication -$2.20 or -2.96%
Intellia Therapeutics (NTLA +$4.54 after Tuesday’s -$19.00 and Monday’s +$2.49 after Friday’s +$8.90) with a pre-open indication $0.00 or 0%
Caribou Therapeutics (CRBU -$0.06 after Tuesday’s N/A and Monday’s $0.11) with a pre-open indication -$0.04 or -0.43%
BUY:
Editas Medicine (EDIT -$0.34 after Tuesday’s +$0.37 after Monday’s $0.22) with a pre-open indication +$0.60 or +3.50%
CRISPR Therapeutics (CRSP +$1.34 after Tuesday’s -$3.93 after Monday’s +$1.64 after Friday’s +$2.57) with a pre-open indication $0.85 or +4.86%
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed up +$0.34 with 649 shares traded after Tuesday’s -$0.04 with 4,359 shares traded after Monday’s +$0.37 with 687 shares traded after Friday’s flat with 70 shares traded after Thursday’s -$0.62 with a “sudden block” of 1,259 share traded after Wednesday’s +$0.20 with an “out-of-the air” block of 3,070 after Tuesday’s +$0.62 with 4,225 shares traded – doesn’t the term – “zombie” fit this equity.
WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
· Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: A positive sector close on Wednesday after a negative Tuesday close started the month of March.
However, volume remains low in the sector; which questions the potential of a follow-through sector session tore- confirm another positive close.
So, until the major indexes reclaim their 21-day line and the market rally has a follow-through day, sector investors should keep your exposure modest.
The downside risks remain high.
My select sector cell and gene therapy comparables seem to be holding onto the bulk of their recent gains.
However, given the extreme volatility, sector investors may want to take some profits in some recent winners.
Earnings’ reporting on the horizon:
· Athersys (ATHX), Tuesday, 3/15
· Cellectis SA (CLLS) Thursday, 3/22
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
